Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript

featured-image

Lisata Therapeutics, Inc. ( NASDAQ: LSTA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, CEO & Director James Nisco - SVP, Finance, Treasurer, CAO & Principal Financial and Accounting Officer Kristen Buck - EVP, R&D & Chief Medical Officer Conference Call Participants Steve Brozak - WBB Securities Pete Enderlin - MAZ Partners Will Hidell - Brookline Capital Markets Operator Welcome to the Lisata Therapeutics' Third Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, Tuesday, November 12, 2024.

I would now like to turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Lisata. Please go ahead, sir. John Menditto Thank you, operator, and good afternoon, everyone.



Welcome to Lisata's Third Quarter 2024 conference call to discuss our financial results and to provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer; Dr.

Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer; and James Nisco, Senior Vice President of Finance and Treasury and Chief Accounting Officer. Shortly before this call, we issued a press release announcing our third quarter 2024 financial results, which is available under the Investors and News section of the company website, along with a webcast replay of this call. If you have not received this news release or you'd like to be added to the company's e-mail distribution list, please subscribe to our e-mail alerts on the company website or e-mail me at jmenditto@lisata.

com to be added. Before we begin, I remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties.